No Detail Found!

BIOEQUIVALENCE EVALUATION OF TWO CLARITHROMYCIN TABLET FORMULATIONS: A RANDOMIZED, SINGLE-DOSE, OPEN-LABEL, TWO-TREATMENT PERIOD CROSS OVER STUDY IN HEALTHY MALE PAKISTANI VOLUNTEERS

Author(s)
Samiullah Department of Pharmacy,University of Peshawar, Peshawar, Pakistan
Zafar Iqbal Department of Pharmacy,University of Peshawar, Peshawar, Pakistan
Yasar Shah Department of Pharmacy,Abdul Wali Khan University,Mardan, Pakistan
Muhammad Imran Khan Department of Pharmacy,Women Institute of Learning,Abbottabad, Pakistan
Abad Khan Department of Pharmacy,University of Swabi, Swabi, Pakistan
Zahid Nazar Department of Psychiatry,Lady Reading Hospital, Peshawar, Pakistan
Obaidullah Department of Agricultural Chemistry, The University of Agriculture, Peshawar, Pakistan
Abstract
To conduct the bioequivalence study of commercially available two brands of clarithromycin tablets (500 mg) in healthy Pakistani male volunteers. Methodology: The study was performed using a randomized, open labeled, two treatment periods and cross over study design. Healthy volunteers (n =12) were recruited following strict inclusion criteria. Their blood samples were collected at various time intervals over a period of 24 hrs after oral administration of test and reference formulations of clarithromycin tablets (500 mg). A validated reversed-phase high performance liquid chromatographic method with ultraviolet detection (RP-HPLC-UV) was used for the quantification of plasma concentrations of clarithromycin. Various pharmacokinetic parameters were determined using non-compartmental analysis approach. Results: The Cmax, tmax, AUC0-t and half-life (t1/2) values of clarithromycin from test formulation were 2.882 ±0.13 µg/mL, 1.75 ±0.45 hr, 11.33 ±0.68 µg.hr/mL and 2.84 ±0.17 hr, while for reference formulation these were 3.089 ±0.19 µg/ mL, 1.83 ±0.39 hr, 12.87 ±1.09 µg.hr/mL and 3.10 ±0.28 hr, respectively. The 90% confidence interval values of Cmax, tmax, AUC0-t and half life for test and reference formulations of clarithromycin were 0.89-0.98, 0.80-1.14, 0.84-0.93 and 0.88-0.95, respectively, which satisfied the acceptance ranges of WHO and FDA bioequivalence guidelines i.e., 0.80-1.25. Similarly, in-vitro evaluation studies were also performed for both test and reference formulations of clarithromycin as specified in the official monographs in USP-30. Both formulations qualified all the in-vitro tests as per specifications in their respective monographs. The f1 and f2 values were also within the acceptance ranges for test and reference formulations. Conclusion: The test and reference formulations of clarithromycin were bioequivalent.
Publication Details
Page(s) 176-183
DOI DOI not available
Published Journal: Journal of Postgraduate Medical Institute, Volume: 31, Issue: 2, Year: 2017

Request the full text from PASTIC

Keywords
pharmacokinetics, Clarithromycin, bioequivalence, RP-HPLC-UV
0

Citations

0

Downloads

39

Views